Transgene Statistics

Total Valuation

Transgene has a market cap or net worth of GBP 76.49 million. The enterprise value is 94.43 million.

Market Cap	76.49M
Enterprise Value	94.43M

Important Dates

The next estimated earnings date is Thursday, March 27, 2025.

Earnings Date	Mar 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.17%
Shares Change (QoQ)	-0.42%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	34.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.86
EV / Sales	17.39
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.87

Financial Position

The company has a current ratio of 1.57

Current Ratio	1.57
Quick Ratio	1.40
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.95
Interest Coverage	-46.46

Financial Efficiency

Return on equity (ROE) is -214.69% and return on invested capital (ROIC) is -54.54%.

Return on Equity (ROE)	-214.69%
Return on Assets (ROA)	-38.85%
Return on Invested Capital (ROIC)	-54.54%
Return on Capital Employed (ROCE)	-80.81%
Revenue Per Employee	37,711
Profits Per Employee	-133,044
Employee Count	141
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.05% in the last 52 weeks. The beta is 0.75, so Transgene's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-49.05%
50-Day Moving Average	0.89
200-Day Moving Average	1.57
Relative Strength Index (RSI)	40.25
Average Volume (20 Days)	296

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Transgene had revenue of GBP 5.51 million and -19.42 million in losses. Loss per share was -0.19.

Revenue	5.51M
Gross Profit	-19.46M
Operating Income	-26.43M
Pretax Income	-19.42M
Net Income	-19.42M
EBITDA	-25.47M
EBIT	-26.43M
Loss Per Share	-0.19

Full Income Statement

Balance Sheet

The company has 12.99 million in cash and 31.19 million in debt, giving a net cash position of -18.20 million.

Cash & Cash Equivalents	12.99M
Total Debt	31.19M
Net Cash	-18.20M
Net Cash Per Share	n/a
Equity (Book Value)	-522,257
Book Value Per Share	-0.01
Working Capital	5.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -30.13 million and capital expenditures -2.77 million, giving a free cash flow of -32.91 million.

Operating Cash Flow	-30.13M
Capital Expenditures	-2.77M
Free Cash Flow	-32.91M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-480.04%
Pretax Margin	-352.80%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Transgene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.17%
Shareholder Yield	-1.17%
Earnings Yield	-25.40%
FCF Yield	-43.02%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Transgene has an Altman Z-Score of -3.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.44
Piotroski F-Score	n/a